NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Duarte A, Mebrahtu T, Goncalves PS, et al. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2017 Nov. (Health Technology Assessment, No. 21.64.)
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Show detailsThe potential extra cost to the NHS of providing adalimumab, etanercept or ustekinumab to children and young people with moderate to severe plaque psoriasis is largely uncertain, given the paucity of evidence on the health-care resource use specific to this population and the uncertainties in the effectiveness evidence base. The resource use associated with BSC in terms of the expected number of hospitalisations per annum was identified as a key area of uncertainty, as in previous TAs of psoriasis in adults. Reducing uncertainty at this level would allow a more accurate assessment of the potential impact on the consumption of NHS resources of providing biological treatment to children and young people with moderate to severe plaque psoriasis.
- Assessment of factors relevant to the NHS and other parties - Adalimumab, etaner...Assessment of factors relevant to the NHS and other parties - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
- Economic model: evidence-based pathway - Risk assessments and structured care in...Economic model: evidence-based pathway - Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model
- Introduction - Clinical effectiveness and patient perspectives of different trea...Introduction - Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis
- Trial management, governance and conduct - The Age of BLood Evaluation (ABLE) ra...Trial management, governance and conduct - The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost–utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up
- Assessment of cost-effectiveness - Biomarkers for assessing acute kidney injury ...Assessment of cost-effectiveness - Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis
Your browsing activity is empty.
Activity recording is turned off.
See more...